Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 26, 2003. The report details specific corporate actions regarding share re-purchases and changes in director shareholdings rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to a specific share transaction:
- Share Re-purchase Price: 1,106.29 pence per share.
- Shares Purchased: 800,000 Ordinary 25 pence shares.
Material Changes
The filing reports the following material corporate actions:
- Share Cancellation: On February 25, 2003, the company purchased 800,000 shares for cancellation under authority granted at the May 20, 2002 Annual General Meeting.
- Director Interests: On February 26, 2003, Director Mr. J D Coombe facilitated the transfer of shares from two discretionary trusts to his three adult daughters:
- 3,623 shares transferred from The J D Coombe 1999/1 Discretionary Trust.
- 9,618 shares transferred from The G A Coombe 1999/1 Discretionary Trust.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items beyond the disclosed share transactions.
Investor Verification Points
- Verify the total number of shares remaining in the company's treasury or authorized for future re-purchase following the cancellation of 800,000 shares.
- Confirm the total cost of the re-purchase transaction (800,000 shares at 1,106.29 pence).
- Review the updated shareholding register to reflect the transfer of 13,241 shares from Mr. Coombe's trusts to his beneficiaries.